Target
PDGFR-alpha
23 abstracts
Abstract
RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,
Abstract
Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.Org: The Third Affiliated Hospital Kunming Medical University,
Abstract
The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,
Abstract
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,
Abstract
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,
Abstract
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.Org: Weill Medical College at Cornell University,
Abstract
Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.Org: Halifax, NS, Canada, Winnipeg, MB, Canada,
Abstract
Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Abstract
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.Org: PLA General Hospital,
Abstract
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,
Abstract
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).Org: First People’s Hospital of Foshan, Foshan First People's Hospital,
Abstract
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.Org: the Naval Medical University,
Abstract
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.Org: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Northshore University Healthsystem, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.Org: The Second Affiliated Hospital of Air Force Medical University, Xi'an Medical College,
Abstract
Expanding the spectrum of neoplasms harboring EWSR1::CREM fusion as detected by a real-world clinical genomics platform.Org: University of Miami Hospital/Jackson Memorial Hospital, Caris Life Sciences, Irving, TX, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study.Org: The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China,
Abstract
Chondrosarcoma: The OSU experience.Org: The Ohio State University Medical Center, The Ohio State University - James Cancer Hospital, Ohio State University James Cancer Hospital Department of Radiation Oncology, Ohio State University Hospital, The Ohio State University - James Cancer Hospital and Solove Research Institute,
Abstract
Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,
Abstract
Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.Org: Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center and Sun Yat-sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib.Org: Rush University Medical Center,